Gene test may guide breast cancer treatment decisions
NCT ID NCT06723990
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a genetic test called HER2DX can help doctors decide on the best treatment for people with early-stage HER2-positive breast cancer. The study will enroll 60 patients and observe how often the test results change the treatment plan recommended by a team of specialists. The goal is to see if the test improves confidence in treatment choices, not to directly test a new drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HER2DX genetic test
- What this could lead to
- If successful, this could show that a genetic test helps doctors personalize treatment for HER2+ breast cancer, potentially improving outcomes and reducing unnecessary side effects.
- What could go wrong
- This is a small, observational study (60 people) at one center. It only measures if doctors change their decisions, not if those changes actually improve patient health. The test may not be widely adopted or beneficial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER EARLY STAGE BREAST CANCER (STAGE 1-3) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Istituto Europeo di Oncologia
RECRUITINGMilan, Italy, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Exercise during chemo: a new weapon to preserve strength?
- Could a smartphone program ease Chemo's emotional toll?
- Could fewer heart tests be safer for breast cancer patients?
- New study aims to predict who will respond to breast cancer therapy
- Blood test could revolutionize breast cancer monitoring
- Tech trio aims to help breast cancer survivors remember daily pills